The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis

Journal of Nuclear Medicine

Volumn 53, Issue 10, 2012, Pages 1543-1549

  Sobic Saranovic, Dragana ^a,b   Grozdic, Isidora ^b   Videnovic Ivanov, Jelica ^b   Vucinic Mihailovic, Violeta ^a,b   Artiko, Vera ^a,b   Saranovic, Djordjije ^a,b   Djuric Stefanovic, Aleksandra ^a,b   Masulovic, Dragan ^a,b   Odalovic, Strahinja ^b   Ilic Dudvarski, Aleksandra ^a,b   Popevic, Spasoje ^b   Pavlovic, Smiljana ^a,b   Obradovic, Vladimir ^a,b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

18F FDG PET CT; ACE; Clinical management; MDCT; Sarcoidosis

Indexed keywords

CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; DIAGNOSTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT PLANNING; BLOOD; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; CHRONIC DISEASE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; SARCOIDOSIS;

EID: 84867083327     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.104380     Document Type: Article

References (38)

1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153-2165.
2. Cox CE, Davis-Allen A, Judson MA. Sarcoidosis. Med Clin North Am. 2005;89:817-828. (Pubitemid 40755546)
3. Malaisamy S, Dalal B, Bimenyuy C, Soubani AO. The clinical and radiologic features of nodular pulmonary sarcoidosis. Lung. 2009;187:9-15.
4. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS), and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736-755.
5. McGrath DS, Foley PJ, Petrek M, et al. Ace gene I/D polymorphism and sarcoidosis pulmonary disease severity. Am J Respir Crit Care Med. 2001;164:197-201. (Pubitemid 34001281)
6. Maña J, Game C. Molecular imaging in sarcoidosis. Curr Opin Pulm Med. 2011;17:325-331.
7. Akira M, Kozuka T, Inoue Y, Sakatani M. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest. 2005;127:185-191. (Pubitemid 41724575)
8. Lebtahi R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med. 2001;42:21-26. (Pubitemid 32104772)
9. 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47:1571-1576.
10. Schuster DM, Alazraki N. Gallium and other agents in diseases of the lung. Semin Nucl Med. 2002;32:193-211. (Pubitemid 34803592)
11. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647-1649.
12. Krüger S, Buckb AK, Mottaghyb FM, et al. Use of integrated FDG-PET/CT in sarcoidosis. Clin Imaging. 2008;32:269-273. (Pubitemid 351899275)
13. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23:315-340. (Pubitemid 37431265)
14. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med. 2004;34:313-329. (Pubitemid 39366000)
15. Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJG. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med. 2010;51:1937-1949.
16. Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics. 2005;25:1357-1368. (Pubitemid 41695350)
17. Prabhakar HB, Rabinowitz CB, Gibbons FK, O'Donnell WJ, Shepard JA, Aquino SL. Imaging features of sarcoidosis on MDCT, FDG PET and PET/CT. AJR. 2008;190(3, suppl)S1-S6. (Pubitemid 351304484)
18. Mostard RLM, Voo S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011;105:1917-1924.
19. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging. 2008;35:1537-1543.
20. Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics. 2004;24:523-543. (Pubitemid 38470893)
21. Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11 1993. Eur Respir J. 1994;7:624-627.
22. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949-1953.
23. Nunes H, Brillet PY, Valeyre D, Brauner MW, Wells AU. Imaging in sarcoidosis. Semin Respir Crit Care Med. 2007;28:102-120. (Pubitemid 46364275)
24. Müller NL, Mawson JB, Mathieson JR, Abboud A, Ostrow DN, Champion P. Sarcoidosis: correlation of CT with clinical, functional, and radiological findings. Radiology. 1989;171:613-618. (Pubitemid 19134907)
25. Remy-Jardin M, Giraud F, Remy J, Wattinne L, Wallaert B, Duhamel A. Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment. Radiology. 1994;191:675-680. (Pubitemid 24177884)
26. Mostard RL, Prompers L, Weijers RE, et al. F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med. 2012;37:21-25.
27. Gilbert S, Steinbrech DS, Landas SK, Hunninghake GW. Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease. Am Rev Respir Dis. 1993;148:483-486. (Pubitemid 23221598)
28. Silverstein E, Friedland J, Lyons HA, Gourin A. Elevation of angiotensin-converting enzyme in granulomatous lymph nodes and serum in sarcoidosis: clinical and possible pathogenic significance. Ann N Y Acad Sci. 1976;278:498-513.
29. Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis: its value in present clinical practice. Ann Clin Biochem. 1989;26:13-18. (Pubitemid 19044155)
30. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging. 2009;36:1131-1137.
31. Lieberman J, Schleissner LA, Nosal A, Sastre A, Mishkin FS. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis: a longitudinal study of serum ACE, 67 gallium scans, chest roentgenograms, and pulmonary function. Chest. 1983;84:522-528. (Pubitemid 14228960)
32. Kaira K, Ishizuka T, Yanagitani N, Sunaga N, Hisada T, Mori M. Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis. Clin Nucl Med. 2007;32:114-116. (Pubitemid 46148392)
33. Milman N, Mortensen J, Sloth C. Fluorodeoxyglucose PET scan in pulmonary sarcoidosis during treatment with inhaled and oral corticosteroids. Respiration. 2003;70:408-413. (Pubitemid 37203362)
34. 18F-FDG PET in sarcoidosis: and observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2008; 25:143-149.
35. Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR. 2000;174:1751-1757. (Pubitemid 30346752)
36. Wells A. High resolution computed tomography in sarcoidosis: a clinical perspective. Sarcoidosis Vasc Diffuse Lung Dis. 1998;15:140-146. (Pubitemid 28466789)
37. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study review. Curr Opin Pulm Med. 2002;8:470-476. (Pubitemid 34836955)
38. Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med. 2008;102:1-9. (Pubitemid 350151832)